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ABSTRACT
The HIV-1 accessory protein Vif plays a dual role:
it counteracts the natural restriction factors
APOBEC3G and 3F and ensures efficient retrotran-
scription of the HIV-1 RNA genome. We have pre-
viously shown that Vif can act as an auxiliary factor
for HIV-1 reverse transcriptase (RT), increasing its
rate of association to RNA or DNA templates.
Here, by using seven different Vif mutants, we pro-
vide in vitro evidences that Vif stimulates HIV-1 RT
through direct protein–protein interaction, which is
mediated by its C-terminal domain. Physical inter-
action appears to require the proline-rich region
comprised between amino acid (aa) 161 and 164 of
Vif, whereas the RT stimulatory activity requires, in
addition, the extreme C-terminal region (aa 169–192)
of the Vif protein. Neither the RNA interaction
domain, nor the Zn
++-binding domain of Vif are
required for its interaction with the viral RT.
Pseudotyped HIV-1 lentiviral vectors bearing Vif
mutants deleted in the RNA- or RT-binding domains
show defects in retrotranscription/integration pro-
cesses in both permissive and nonpermissive
cells. Our results broaden our knowledge on how
three important functions of Vif (RNA binding,
RT binding and stimulation and Zn
++ binding), are
coordinated by different domains.
INTRODUCTION
The human immunodeﬁciency virus (HIV) virion infectiv-
ity factor (Vif) is essential for eﬃcient viral replication in
natural target cells (1–3). Vif counteracts the action of the
cytosine deaminases APOBEC3G (4) and APOBEC3F
(5), that, in the absence of Vif, are incorporated into
viral particles and, in the subsequent round of infection,
deaminate C to U residues in newly synthesized HIV
minus strand DNA, leading to G–A mutation in the
HIV proviral DNA (6–10). In infected cells, Vif binds
APOBECs and target them to degradation through
recruitment of the ubiquitination enzymes ElonginB, C
and Cullin 5, thereby preventing APOBECs incorporation
into HIV-1 virions (11–15). The analysis of virions pro-
duced in nonpermissive cells in the absence of Vif led
to conﬂicting reports, showing that they either have
normal viral protein and RNA content (3,16–19), or
show abnormal virion morphology (20–22). Nonetheless,
a full consensus exists about the observation that Vif-
deﬁcient HIV-1 viruses produced in nonpermissive
cells, enter the target cells normally but are defective in
the production of reverse transcription products (2,3,
23–25). Although the Vif interactions with APOBEC3
ElonginB, C and Cullin 5 proteins are clearly important
for virus replication and pathogenesis, Vif seems to have
nonessential interactions with other viral proteins. For
example, a role of Vif in the reverse transcription process
has been postulated. Interestingly, Vif has been detected in
HIV virions (17,26,27), binds the viral RNA (28–30), is a
component of the reverse transcription complex in HIV-1
infected cells and is required for eﬃcient reverse transcrip-
tion in vitro and in vivo (29,31,32). We have previously
shown that Vif stimulates the eﬃciency of HIV-1 reverse
transcriptase (RT) in vitro, by increasing the rate of asso-
ciation of the enzyme to the primer/template and decreas-
ing the thermodynamic barrier for ternary complex
formation (33). However, the mechanistic details of this
functional interaction are still unknown. One obvious
question is whether this stimulation was dependent on
direct protein–protein interaction between Vif and RT
and/or on the interaction of Vif with the nucleic acid tem-
plate. In this work, we characterized the biochemical
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showing that Vif physically interacts with HIV-1 RT
and stimulates its catalytic activity through two indepen-
dent domains located at its C-terminus. Moreover, we
demonstrate here that neither the RNA binding nor the
Zn
++-ﬁnger domains are required for this interaction.
By using pseudotyped lentiviral vectors (LVs), we show
that both the RNA-binding and the RT-binding
functions are important for eﬃcient retrotranscription/
integration of lentivirus, independently from the presence
of APOBECs. Our results indicate Vif as the bridging
factor in a complex network of potentially competing pro-
tein–protein interactions which are mediated by indepen-
dent functional Vif domains.
MATERIALS AND METHODS
Cells
The HEK-293T cells were propagated in Iscove’s
Modiﬁed Dulbecco’s Medium (IMDM) supplemented
with 10% fetal calf serum (FCS) (EuroClone Ltd,
Paington, UK) and a combination of penicillin–strepto-
mycin and glutamine (PSG). SupT1 and CEMss T-cell
lines were grown in RPMI 1640 containing 10% FCS
and PSG.
Chemicals
[
3H] dTTP (40Ci/mmol) and [g-
32P] ATP (3000Ci/mmol)
were from GE Healthcare and unlabeled dNTP’s from
Roche Molecular Biochemicals. Whatman was the sup-
plier of the GF/C ﬁlters. All other reagents were of ana-
lytical grade and purchased from Merck or Fluka.
Nucleic acids substrates
The homopolymeric template poly(rA200)/oligo(dT20)10:1
(Roche Molecular Biochemicals) was prepared as
described (33). The 40-mer Poly(rA) oligonucleotide
(polyrA40) was purchased by MWG (Florence, Italy).
Mutagenesis
Deletion mutants of HIV-1 were generated by polymerase
chain reaction (PCR)-mediated mutagenesis using the
WT-VifPLNGFR plasmid as DNA template (34).
The gene fragments corresponding to amino acids (aa)
44–192 (VifN1-43), aa 1–140 [VifC(141–192)], aa
1–143 [VifC(144–192)], aa 1–160 [VifC(161–192)] or
aa 1–168 (VifC169–192) were ampliﬁed with speciﬁc pri-
mers. Chim3 gene encodes a chimeric protein in which a
45-aa-spanning region of F12-Vif (aa 126–170) (34) is
embedded in the wt-Vif backbone. Chim3 gene was gen-
erated by DNA synthesis (Primm s.r.l, Milano). The PCR-
generated and Chim3 mutants were then inserted into
pGEX-T4-1 vector for Escherichia coli expression and iso-
lation of GST-Vif fusion protein. The recombinant plas-
mids were constructed by replacing the BamHI–NotI
fragment of pGEX with the PCR ampliﬁed Vif gene,
either full length or the truncated versions. The triple
mutant P161A, P162A, P164A, Vif(3P3A) was obtained
from Bio-Fab Research Ltd. (Rome, Italy). All the
recombinant proteins were expressed and puriﬁed as
described below.
Protein expression, purification and western blot analysis
The vector pGEX with the wild type or mutated Vif gene
was transformed into BL21 competent cells (Novagen,
Madison WI). After growth at 378C up to optical density
of  0.6, the expression of GST-Vif proteins was induced
by adding 1mM of isopropylthio-b-D-galactoside (IPTG).
The bacterial cells were lysed by adding lysis buﬀer
(0.25M Tris–HCl pH 7, Triton X-100 1%, SDS 0.03%,
NP-40 0.5%, Tween-20 0.1%, dithiothreitol (DTT) 5mM,
lysozyme 1mg/ml) followed by sonication. The superna-
tants have been conserved and the pellets were resus-
pended by adding 5 vol of urea buﬀer (NaPO4 0.1M,
0.01M Tris–HCl pH 8, NP-40 0.01%, urea 6M) and soni-
cated. The supernatant has been inserted into a dialysis
membrane (Pierce, Thermo Fischer Scientiﬁc) and left
overnight at 48C under magnetic stirring in dialysis
buﬀer (Tris–HCl pH 7, 0.25M, Triton X-100 1%, SDS
0.03%, NP-40 0.5%, Tween-20 0.1%, DTT 5mM). The
supernatants were applied to equilibrated gluthathione-
conjugated GSH-Sepharose beads (GE Healthcare) and
left shaking overnight at 48C. Then, the samples were
centrifuged and the supernatants were conserved (ﬂow-
through). The beads were washed in PBS and then
eluted with the Elution Buﬀer (PBS 1X pH 7.4, GSH
0.03%) for 3h at 48C. Eluted fractions containing GST-
Vif were stored at –808C. Samples were analyzed by west-
ern blotting with primary antibodies goat anti-GST-rabbit
and HRP-anti-Rabbit IgG antibody as the secondary anti-
body. A chemiluminescence-based system (Pierce Thermo
Scientiﬁc) was applied to visualize the reacting bands.
Proteins were 90% pure as judged by Coomassie staining
of SDS–PAGE.
Enzymatic assays
RNA-dependent DNA polymerase RT activity was
assayed as described (33). Brieﬂy, a 25-ml ﬁnal reaction
volume contained TDB buﬀer [50mM Tris–HCl pH 8.0,
1mM DTT, 0.2mg/ml bovine serum albumin (BSA], 2%
glycerol), 10mM MgCl2, 0.5mg of poly(rA):oligo(dT)10:1
(0.3mM3 0–OH ends), 10mM
3[H]dTTP 1Ci/mmol,
5–10nM RT and the indicated amounts of recombinant
Vif proteins. After incubation at 378C for indicated time,
20ml from each reaction tube were spiked on glass ﬁber
ﬁlters GF/C and, immediately, immersed in 5% ice-cold
trichloroacetic acid (TCA) (AppliChem GmbH,
Darmstadt). Filters were washed three times with 5%
TCA and once with ethanol for 5min, then dried and,
ﬁnally, added with EcoLume Scintillation cocktail
(ICN, Research Products Division, Costa Mesa, CA,
USA), to detect the acid-precipitable radioactivity by
PerkinElmer Trilux MicroBeta 1450 Counter.
Electrophoretic mobility shift gel assay (EMSA)
Puriﬁed recombinant Vif proteins were incubated 5min
at 378C in the presence of 50-labeled poly(rA40), in 10ml
of reaction buﬀer (50mM Tris–HCl pH 7.0, 0.25mg/ml
BSA, 1mM DTT and 1mM Mg
++). Samples were mixed
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0.25% bromophenol blue] and subjected to PAGE on a
5% native gel at 48C for 2h at 5V/cm. Position of the free
probe and of the protein–DNA complexes on the gel was
visualized by laser scanning densitometry.
Zn
++-binding assay
Recombinat Vif proteins were incubated overnight at 48C
in the presence of PBS 1X containing 100mM of the
Zn
++-chelating agent N,N,N,N-tetrakis-(2-pyridyl-
methyl)-ethylenediamine (TPEN, Sigma-Aldrich). Next,
the proteins were dialyzed against PBS 1X to remove
TPEN and immediately applied to a FPLC-HiTrap
IMAC FF column (GE Healthcare) previously charged
with Zn
++ according to the manufacturer’s protocol
and subsequently equilibrated in PBS 1X. Column was
washed with PBS 1X and eluted with a linear 0–0.5M
gradient of Imidazole in PBS 1X. Collected fractions
were subjected to SDS–PAGE and transferred to a nitro-
cellulose membrane. Proteins were visualized by immuno-
blot with anti-GST antibodies. In a control experiment
performed with GST only, no GST protein was retained
on the column (data not shown).
Pull-down experiments
For the pull-down assays, 5mg of his-RT and 5mg of the
GST-Vif-wt and GST-Vif-mutant proteins were used.
After incubation on ice for 10 minutes, either GSH-
Sepharose or Ni-NTA Agarose Beads (QIAGEN) were
added, formerly equilibrated in PBS 1X. The proteins
were incubated for an hour at 48C and then centrifuged
for 2min. The supernatants were conserved in order to be
analyzed on SDS–PAGE gels. The beads were washed
twice in PBS 1X and ﬁnally resuspended in Tris–HCl
pH 7.5 and Laemmli loading buﬀer 1X and heated for 5
minutes at 1008C. All samples were centrifuged in order to
be electrophoresed in SDS–PAGE gels 12%. The gels were
dried, transferred to nitrocellulose membranes and ana-
lyzed by western blotting.
Kinetic analysis
Reactions were performed under the conditions described
for the HIV-1 RT activity assay. The dependence of the
initial velocity of the reaction as a function of variable
nucleic acid substrate concentrations (0–300nM) was
measured in the absence or in the presence of ﬁxed increas-
ing amounts (0–40nM) of the various Vif proteins.
Kinetic parameters (kcat, Km, kcat/Km) were determined
by nonleast squares computer ﬁtting methods utilizing
the Michelis–Menten equation. Values used were the
means of three independent experiments.
Pseudotyped LVS generation and cellular transduction
by LVs
The LVs PLNGFR (empty vector) bearing an internal
PGK-LNGFR selection marker cassette, and the wt
Vif-PLNGFR, bearing the WT-Vif under the trans-
criptional control of the 50 LTR of the vector, were pre-
viously described in (34). The VifN-LNGFR and
VifC-LNGFR LVs were generated by inserting the
447-bp and 423-bp PCR amplicons, respectively, in the
ClaI site of the PLNGFR empty vector. To amplify
the two Vif fragments, the wt-VifPLNGFR plasmid,
as DNA template, and the following primers were used:
for the VifN fragment:
Forward: 50CCA TCG ATG GAT GAG TAC TAA
TCC AAA AAT AAG TT-30
Reverse: 50CTC CTC TAA TCG ATG CTA GTG TCC
ATT CAT TG-30
for the VifC fragment:
Forward: 50GCA AAG AAT CGA TGG GAT TAT
GGA AAA CAG-30
Reverse: 50CCA TCG ATG GCT AGT TAT GTC
CTG-30
VSV-G pseudotyped LV stocks were produced by tran-
sient co-transfection of 293T cells with the transfer vectors
described above, a second-generation packaging construct
pCMVR8.74 and the pMD.G plasmid encoding the
vesicular stomatitis envelope glycoprotein (VSV-G) (34).
Viral particles were normalized by RT activity assay and
by p24Gag Ag ELISA (COULTER test kit, Beckman
Coulter, Fullerton, CA, USA) following manufacturer’s
instructions. Viral infectivity/integration of the VSV-G
pseudotyped LVs was tested by spinoculating SupT1
and CEM A3.01 cells with RT activity-normalized
amounts of LVs in the presence of polybrene (8mg/ml),
monitored 7 days after transduction by ﬂow cyto-
metry analysis of LNGFR expression using the anti-
human LNGFR monoclonal antibody C40-1457 (BD
Pharmingen
TM), as previously described (34).
HIV-1 infection and RT activity assay
SupT1 and CEMss cells were acutely infected with the
molecular clones X4 HIV-1NL4-3 and its Vif-deﬁcient
(vif) derivative, which were produced by transient trans-
fection of the corresponding plasmids in HEK-293T cells.
Forty-eight hours after transfection, supernatants were
collected, ﬁltered and tested for RT activity. Equal
amount of viruses were adsorbed to the cells for 2–5h
at 378C, then washed out twice with PBS. Cells were
eventually resuspended in complete medium and seeded
at 0.5–1 10
6/ml in triplicate in 96-well plate. Culture
supernatants were harvested every 4 days and stored at
–808C until tested for Mg
2+-dependent RT-activity
assay following standard procedures (34).
RESULTS
HIV-1 Vif physically interacts with the viral reverse
transcriptase through its C-terminal domain
We produced recombinant Vif fused to GST (GST-Vif)
and recombinant RT fused to a six histidine tag (his-
RT). The availability of two diﬀerent tags allowed us to
probe these proteins for physical interaction in pull-down
assays. The schematic diagram of the various Vif proteins
used is shown in Figure 1, along with their phenotypes, as
3662 Nucleic Acids Research, 2009, Vol. 37,No. 11revealed in this study. As shown in Figure 2A, full-length
HIV-1 Vif was able to pull down HIV-1 RT, thus demon-
strating a direct protein–protein interaction between these
two proteins. By comparing two Vif mutants, one lacking
the ﬁrst 43 aa at its N-terminal (VifN1-43 aa) and one
lacking the last 51 aa (VifC141–192), for their ability
to stimulate the catalytic activity or HIV-1 RT, we have
previously hypothesized that the C-terminal domain was
important for this function, since the VifC141–192 could
not stimulate RT activity (33). The VifN1–43 and
VifC141–192 mutant proteins were then tested in pull-
down assays for interaction with HIV-1 RT. The
VifN1-43 mutant was able to physically interact with
HIV-1 RT (Figure 2B), whereas the C-terminal deletion
in VifC141–192 prevented physical interaction between
Vif and RT (Figure 2C). Thus, the RT interaction domain
of Vif could be assigned to the last 51 aa of the protein.
We applied the same type of analysis to the Vif mutant
Chim3, derived from the natural mutant F12-Vif (35).
The Chim3 mutant contains ﬁve unique point mutations
in the Zn
++-ﬁnger domain (aa 128–133 NV-V-RLS).
As shown in Figure 2G, Chim3 was able to physically
interact with HIV-1 RT. Next, wt Vif and the mutants
Chim3, C and N were tested for their eﬀects on
HIV-1 RT activity in vitro (Figure 2I). Wild-type Vif,
the Chim3 and the N mutants were able to increase
the nucleic acid substrate utilization eﬃciency (kcat/Km)
of HIV-1 RT, whereas C was not. These results identify
the C-terminal domain of Vif as essential for the inter-
action with HIV-1 RT.
The physical interaction of HIV-1 Vif with the viral reverse
transcriptase and the stimulation of reverse transcription
activity are mediated by two separate domains
In order to further deﬁne the domain responsible for
the physical and functional interaction between HIV-1
RT and the Vif protein, we constructed three additional
Vif mutants carrying progressively shorter deletions at
the C-terminus (VifC144–192, VifC161–192 and
VifC169–192). Only the VifC169–192 mutant was
able to physically interact with HIV-1 RT in a pull-
down assay (Figure 2F), whereas the other two mutants
carrying the aa144–192 and aa161–192 deletions were not
(Figure 2D and E). However, when tested in an in vitro RT
assay, the VifC169–192 was found to strongly inhibit the
reaction (Figure 2L). These results show that physical
interaction between Vif and RT is mediated by the aa
161–168 of Vif, whereas the stimulatory activity requires,
in addition, the extreme C-terminal region (aa 168–192) of
the protein. In order to further deﬁne the interaction
domain of Vif with RT, we created a triple mutant
P161A, P162A, P164A, called ‘Vif(3P3A)’ and evaluated
its ability to physically and functionally interact with
HIV-1 RT. As shown in Figure 2H and I, the Vif(3P3A)
mutant was not able to pull down the recombinant RT,
nor to stimulate the HIV-1 RT activity, indicating that the
161–164 Pro-rich domain was important for the RT–Vif
interaction.
RNA binding is not required for the functional interaction
of Vif with HIV-1 reverse transcriptase
Both HIV-1 RT and Vif can bind RNA. In order to verify
whether the observed stimulation of RT activity by
Vif required also interaction of Vif with the RNA tem-
plate, we tested our panel of mutants for their ability to
interact with RNA in EMSAs. As shown in Figure 3,
among the mutants tested, only the VifN lost its ability
to interact with RNA. Since this mutant retained full
ability to stimulate HIV-1 RT, we can conclude that
the functional interaction between Vif and RT does not
require RNA binding. The mutants VifC144–192,
VifC161–192 and Vif 3P3A were also similarly tested
Figure 1. Schematic representation of the diﬀerent Vif mutants used in this study along with their phenotypes. The Zn
++-ﬁnger domain (aa
108–139) is shaded in gray. The histidines (H) and cysteines (C) essential for Zn
++ binding are indicated in bold letters. The ﬁve unique mutated
aa present within the Chim3 Zn
++-ﬁnger are indicated in bold italic letters. The position of the three Ala mutated to Pro residues in the Vif3P3A
mutant are indicated. n.d.: not determined. + sign identiﬁes positive interaction,   sign identiﬁes lack of interaction.
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The RNA-binding domain of Vif has been previously
located in the N-terminal part of the protein (aa 1–64)
(32). We show here that deletion of the ﬁrst 43 aa of Vif
is enough to completely abrogate its RNA-binding activ-
ity, thus further narrowing down the RNA-binding
domain.
The Zn
++-finger domain of HIV-1 Vif is not required
for interaction with RNA or with the viral reverse
transcriptase
HIV-1 Vif contains an H-C2-H Zn
++-ﬁnger domain (aa
108–139), which has been shown to be important for pro-
tein–protein interactions (35–38). Both the VifC and N
mutants retained this domain. Conversely, the Chim3
Figure 2. The C-terminal domain of Vif is required for binding and stimulation of the HIV-1 RT activity. (A) Pull-down assay in the presence of GST-
Vif wild type (lanes 3 and 4), his-tagged RT (lanes 3 and 5) and GSH-sepharose beads (lanes 3–5). Proteins were visualized with antibodies against
the GST- (left part) or the his- (right part) tags, respectively. Lane 1, GST-Vif positive control; lane 2, his-RT positive control. (B) As in (A) but
in the presence of GST–VifN(1–43). (C) As in (A), but in the presence of GST–VifC(141–192). (D) As in (A), but in the presence of GST–
VifC(144–192). (E) As in (A), but in the presence of GST–VifC(161–192). (F) As in (A), but in the presence of GST–VifC(169–192). (G) As in(A),
but in the presence of GST–VifChim3. (H) Pull down assay in the presence of his-RT and GST-Vifwt or GST-Vif(3P3A). (I) Variation of the nucleic
acid substrate utilization eﬃciency (kcat/Km30OH) of HIV-1 RT as a function of increasing amounts (7.5nM, 15nM, 25nM and 40nM) of Vif wild type
(circles), Chim3 (triangles), VifN(1–43) (squares) and VifC(141–192) (diamonds). Error bars are  SD of three independent replicates. (L) Variation
of the velocity of the reaction catalyzed by HIV-1 RT as function of increasing nucleic acid substrate concentrations, in the absence (circles) or in the
presence of 80-nM wild-type Vif (circles), 80-nM VifC(169–192) or 20-nM VifC(169–192). Error bars are  SD of three independent replicates.
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domain. Since the functionality of the Zn
++-ﬁnger
domain strongly relies on proper folding, which might
have been aﬀected by the deletions/mutations, we directly
veriﬁed the ability of the diﬀerent mutants to bind
to a Zn
++-based aﬃnity column (HiTrap-IMAC, see
‘Materials and Methods’ section). Wild-type Vif
(Figure 4A) and the N (Figure 4B) mutant were retained
on the column, whereas the C141–192 (Figure 4C) and
Chim3 (Figure 4D) mutants were not. The inability of the
Vif C141–192 mutant to bind Zn
++ is likely due to
misfolding of the H-C2-H domain, suggesting that addi-
tional amino acids in the close proximity of the His139, on
the C-terminal side of the protein, are important for sta-
bilization of this domain. Anyhow, the fact that the
Chim3 mutant bearing a nonfunctional Zn
++-ﬁnger was
still able to interact physically and functionally with RT
(Figure 2C), demonstrated that the Zn
++-ﬁnger domain
is dispensable for interaction of Vif with HIV-1 RT. In
addition, the fact that both VifC141–192 and Chim3
mutants were able to interact with RNA (Figure 3), indi-
cated that the Zn
++-ﬁnger domain is also dispensable for
interaction of Vif with the nucleic acid lattice.
The RNA- and reverse transcriptase interacting domains
of Vif are important for viral production and proviral
integration
In order to understand the contribution of the diﬀerent
domains of Vif, identiﬁed in our in vitro studies, on the
reverse transcription and integration process of LVs in
single round infection of human T cells, we produced
recombinant VSV-G-pseudotyped LVs bearing either wt
Vif or the mutants C141–192 and N1–43. LVs in fact
are a good surrogate of HIV-1 infection because they
perform reverse transcription and integrations processes
identically to HIV-1. The diﬀerent LVs were quantiﬁed
by both RT activity assay and p24Gag ELISA. As
shown in Figure 5A, pseudotyped LVs bearing both C
and N mutants showed much lower virus yields (as indi-
cated by the RT activity in the supernatant) than wt Vif.
Next, permissive (SupT1) or non permissive (CEM A3.01)
cells were single round infected with the diﬀerent VSV-
G-pseudotyped LVs (normalized by RT activity) and the
frequency of integration events was measured by FACS
analysis of the constitutive expression of the selection
marker LNGFR LNGFR carried by the LVs (34).
Both permissive (Figure 5B) and nonpermissive
(Figure 5C) cells transduced with the C and N
mutants, consistently showed lower integration levels
than those infected with wt Vif LVs. Psudotyped LVs
carrying no Vif (empty controls) showed even lower inte-
gration levels than the C and N mutants, indicating
that the eﬀects observed for these two mutants were not
due to lack of expression of the mutated Vif proteins. The
defective integration noted for LVs carrying no Vif even in
permissive cells, indicated the importance of Vif for HIV-1
replication also in permissive cells. To further demonstrate
Figure 3. The N-terminal domain of Vif is required for nucleic acid binding. (A) Gel retardation assay in the absence (lane 11) or in the presence
of GST–Vif wild type (lanes 1–5) or GST-Chim3 (lanes 6–10) and a 50-labeled RNA probe (rA40). Protein–RNA complexes were separated from
the free probe on a nondenaturing polyacrylamide gel. (B) The same as in (A), but in the absence (lanes 6 and 12) or in the presence of GST–Vif
wild type (lane 1), GST–VifC(141–192) (lanes 2–5) or GST-VifN(1–43) (lanes 7–11). (C) The same as in (A), but in the presence of GST–
VifC(169–192).
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tion deriving from its interaction with RT, we infected
permissive cells with Vif-proﬁcient and Vif-deﬁcient
HIV-1at two diﬀerent MOI as indicated (Figure S1).
CEMss (panel A and B) and SupT1 (panel C and D)
were followed for 24 days after HIV-1 infection. In all
conditions, it is manifest that the kinetic of infection
of Vif-deﬁcient HIV-1 is delayed and does not reach the
peak of viral production at an extent equivalent to that of
Vif-proﬁcient HIV-1 (Figure S1). These results are in
agreement with our recent results demonstrating that
HIV-1 Vif is involved in the accumulation of retrotran-
scripts during the early steps of HIV-1 life cycle (35).
DISCUSSION
HIV-1 Vif has been proposed to be required for eﬃcient
retrotranscription of the viral RNA genome indepen-
dently of APOBEC3G. Indeed, analysis of the retrotran-
scription complexes (RTCs) formed in the absence of Vif,
revealed structural and functional alterations (21,31,32).
Vif has been detected in HIV virions (17,26,27), binds
the viral RNA (28–30), is a component of the reverse tran-
scription complex in HIV-1-infected cells and is required
for eﬃcient reverse transcription in vitro and in vivo
(29,31–33). However, the mechanistic and molecular
details of this function are poorly known. Here, we pro-
vide evidences that Vif stimulates HIV-1 RT through
direct protein–protein interaction, which is mediated by
its C-terminal domain. Physical interaction appears to
require the region comprised between aa 161 and 168,
particularly the 161–164 Pro-rich domain, whereas the
RT stimulatory activity requires, in addition, the extreme
C-terminal region (aa 169–192) of the Vif protein.
It has been proposed that Vif can act as an RNA
chaperone, thus stabilizing the right conformation of
RTCs and facilitating tRNA primer annealing (39). By
producing Vif mutants deleted in their RNA-binding or
RT-binding domains, we show here that interaction with
RNA is not required for the observed stimulation of
the RT activity by Vif. These results suggest that the
RNA chaperone and RT stimulation activities of Vif are
not interdependent, but can likely act cooperatively to
increase the eﬃciency of the retrotranscription process.
Another domain of Vif important in mediating protein–
protein interactions is the H-C2-H Zn
++-ﬁnger domain
(12,36–38). By using a Vif chimeric mutant (Chim3) which
bears a nonfunctional Zn
++ ﬁnger domain, we demon-
strate here that the ability of Vif to bind Zn
++ is not
required for its functional interaction with RT. In addi-
tion, RNA-binding experiments allowed us to identify the
aa 1–43 as the region of Vif required for RNA binding,
and showed that the Zn
++ ﬁnger domain is not important
for interaction with the nucleic acid.
Experiments with VSV-G-pseudotyped LVs bearing
either wild-type Vif or the C and N mutants, showed
that the absence of either the N-terminal (RNA-binding)
or C-terminal (RT-binding) domains can aﬀect viral pro-
duction and integration, independently from the presence
of APOBECs. A marked reduction in integration levels
was measured for Vif LVs, even in permissive cells
(Figure 5), which correlated with slower replication kinet-
ics of Vif HIV-1 (Figure S1).
A schematic representation of all the protein–protein
interaction domains so far identiﬁed in the protein Vif
is shown in Figure 5D. At least three regions at the
N-terminal part (domain Ia, aa 14–17, Ib, aa 40–44 and
Ic, aa 52–79) have been shown to mediate the interaction
with APOBEC3G-3F (40–42). In the middle part of the
protein there is the Zn
++-ﬁnger (domain II, aa 108–139)
Figure 4. A functional Zn
++-ﬁnger domain is not required for RNA
binding and RT stimulation. (A) Recombinant GST–Vif wild type was
eluted from a Zn
++-chelating column with a linear gradient of imida-
zole. Fractions were immunoblotted with antibodies against GST.
FT, ﬂow through; W, wash. (B) As in (A), but in the presence of
GST–VifN(1–43). (C) As in (A), but in the presence of GST–
VifC(141–192). (D) As in (A), but in the presence of GST–Chim3Vif.
3666 Nucleic Acids Research, 2009, Vol. 37,No. 11which has been implicated in mediating direct interaction
with Cullin 5. At the C-terminus, the bipartite SOCS
Box (domain IIIa, aa 145–149 and IIIb, aa 163–169)
has been suggested to mediate the interaction with
the ElongingBC complex (12,43). Furthermore, the
151–164-region encompassing the 161–164 Pro-rich
domain (domain IV), was shown to be important for Vif
dimerization (44).
Our results indicate that the RNA-binding domain
overlaps with two of the APOBEC3F/G interaction sites
(domain Ia and Ib), whereas the RT interaction domain
spans through the dimerization and ElonginBC-binding
domains. Homology models of Vif tertiary structure
suggested that the Vif C-terminal tail comprising aa
150–192 is likely to be exposed to the solvent, thus repre-
senting a possible interaction domain with host proteins
(45). Moreover, circular dichroism studies of a synthetic
Vif C-terminal domain peptide indicated a high propen-
sion of this domain to assume a disordered structure
unless bound to a ligand (46). Thus, a highly regulated
order of binding must exist, to ensure that Vif correctly
fulﬁlls its various biological functions. HIV-1 viruses lack-
ing Vif can replicate and spread in permissive cells, but
several reports indicated that the absence of Vif often
reduces the replicative ability of these viruses even in the
absence of APOBEC (20,47–50). These observations,
along with the ﬁnding that HIV-1 viruses bearing defective
Vif proteins are circulating in the human population (51)
and that APOBEC proteins can inhibit the viral replica-
tion targeting RT activity in a cytidine deaminase-
independent manner (52), suggest that much has still to
be learned about the Vif-RT-APOBEC axis. Along this
line, our results indicate that three important functions
of Vif (RNA binding, RT binding and Zn
++ binding),
are independently coordinated by diﬀerent domains.
By selectively targeting each of these domains, either
alone or in combination, it would be possible to exploit
novel anti-HIV strategies which combine the highest eﬃ-
cacy in suppressing viral proliferation with the lowest
cytotoxicity.
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Figure 5. The RNA- and RT-binding domain are important for viral replication and integration. (A) RT activity detected in the supernatant of VSV-
G pseudotyped HIV-1-derived LV-producing cells (293T) co-transfected with the transfer vector plasmids carrying no Vif (empty), Vif wild type,
VifN(1–43) or VifC(141–192) together with the packaging and the VSV-G envelope glycoprotein constructs. (B) Frequencies of integration events,
measured as the product of the percent of NGFR
+ cells and the mﬁ values, in permissive cells (SupT1) transduced with LVs bearing no Vif (empty),
Vif wild type, VifN(1–43) or VifC(141–192). (C) The same as in (B), but in nonpermissive cells (CEM A3.01). (D) Schematic representation of the
known functional domains of Vif responsible for its interaction with various proteins. In (A–C), values were the means of three independent
replicates. Statistical analysis was performed by One-way ANOVA–Tukey multiple test. Statistically signiﬁcant diﬀerences from the reference
value (wild type) are indicated by  P<0.1;   P<0.05.
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